Mayo Clinic Feb 12 2026 A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair. However, many tumors eventually stop responding, even when the drugs initially show results. The new research identifies

Tag-uri: DNA